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Background: The purpose of this study was to determine the characteristics of adults with 
type 2 diabetes mellitus (T2DM) that correlate with greater risk of hypoglycemia and determine 
the impact of hypoglycemia on health-related quality of life, work productivity, and medication 
adherence from a patient perspective.
Methods: Data from a large web-based survey were retrospectively analyzed. Adults with a 
diagnosis of T2DM taking antihyperglycemic agents were included in the analysis. Participants 
with knowledge of their hypoglycemic history were divided into three groups: those experienc-
ing recent hypoglycemia (previous 3 months), those experiencing nonrecent hypoglycemia, and 
those never experiencing hypoglycemia.
Results: Of the participants with T2DM taking antihyperglycemic agents who were  knowledgeable 
of their hypoglycemia history, 55.7% had ever experienced hypoglycemia. Of those, 52.7% had 
recent hypoglycemia. Compared with those who never experienced  hypoglycemia, those who 
experienced hypoglycemia tended to: be younger; be more aware of their glycated hemoglobin 
(HbA
1c
) levels; have higher HbA
1c
 levels; have a higher body mass index; have higher Charlson 
Comorbidity Index scores; be on insulin, sulfonylureas, and/or glucagon-like peptide-1 agonists; 
and be less adherent to their antihyperglycemic agents. Hypoglycemia interfered with social activi-
ties, caused more missed work (absenteeism), more impairment while at work (presenteeism), 
and decreased overall work productivity compared with patients who had never experienced 
hypoglycemia. Overall health-related quality of life, as determined by the Short Form-36 health 
questionnaire, was negatively impacted by hypoglycemia. Both Physical and Mental Summary 
scores were significantly lower for the recent hypoglycemia and nonrecent hypoglycemia groups 
compared with the never hypoglycemia group.
Conclusion: Hypoglycemia can negatively impact many aspects of life. Greater awareness of 
those who are at risk for developing hypoglycemia can lead to the development of measures 
(eg, patient and physician education) to prevent future hypoglycemia episodes.
Keywords: adherence, survey, patient preference, burden, antihyperglycemic, low glucose 
effect, hemoglobin A
1C
Introduction
Several large-scale, prospective, randomized trials have documented that lowering 
glycemic levels can prevent the development of microvascular disease in people 
with type 2 diabetes mellitus (T2DM). Consequently, T2DM management guidelines 
 generally recommend a treatment target of glycated hemoglobin (HbA
1c
) levels ,7.0%, 
with some suggesting that even more intensive glycemic goals (,6.5%) would be 
beneficial.1–3 However, one issue with intensive glycemic control is the possibility of 
hypoglycemic events.
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Treatment-related hypoglycemia is known to occur 
in people with T2DM, but its impact from the individual 
patient’s perspective is not well characterized.  Determining 
the impact of hypoglycemia on the lives of people with 
T2DM is very difficult since there is no consensus  definition 
of hypoglycemia. This results in inconsistencies in the 
identification, measurement, and reporting methods across 
studies. The incidence and impact of hypoglycemia can be 
masked by factors such as age, treatment modality, duration 
of diabetes, body weight, and glycemic control.4 The acute 
and chronic complications of hypoglycemia invariably affect 
various aspects of life, including work productivity, social 
interactions, sleep, sexual activity, driving, sport and leisure 
activities, and adherence to therapy.5,6 Acute symptoms can 
be mild (eg, palpitations, tremor, hunger, sweating) or severe 
(eg, behavioral changes, difficulty thinking, confusion, loss 
of consciousness). Long-term complications of hypoglyce-
mia include cardiovascular and neurological complications, 
such as myocardial infarction, arrhythmias, stroke,  cognitive 
decline, dementia, and cardiovascular death.4,7 Health-
related quality of life (HRQoL) may be affected as a result 
of the complications and/or effects of hypoglycemia, or as 
a consequence of avoidant, precautionary, or compensatory 
actions due to the fear of having a hypoglycemia episode.4 
Glycemic control may be an issue since patients who expe-
rience hypoglycemia are more prone to worry about future 
hypoglycemic events and may maintain higher glycemic 
levels to avoid hypoglycemia.5,8 Glycemic control may also 
suffer if health care providers delay advancement of treat-
ment due to similar fears.9 The result is a negative impact on 
overall HRQoL, which has been well documented in studies 
on hypoglycemia in people with T2DM.4,7
There are data to suggest that hypoglycemia can have 
a significant impact on many aspects of the lives of people 
with T2DM. However, there have not been any previous 
studies on the characterizations and impacts of hypogly-
cemia on HRQoL, work productivity, and medication 
adherence in people with T2DM purely based on the patient 
perspective and in a single analysis. In addition, the impact 
of hypoglycemia on these factors in association with gly-
cemic control and burden of disease within the same study 
has not been examined. Consequently, the purpose of this 
study is to retrospectively analyze a large sample of people 
with T2DM to describe their perspectives on the impact of 
hypoglycemia on diabetes and related comorbidity burden, 
HRQoL, and work productivity, as well as the association 
between hypoglycemia and adherence to antihyperglycemic 
medication.
Materials and methods
survey design
The US National Health and Wellness Survey (NHWS) 
is a cross-sectional, Internet-based survey of adults 
aged $18 years. Using a stratified random sampling frame-
work, potential respondents are recruited through Internet 
panels such that the demographic composition of the NHWS 
is identical to that of the general population, as measured by 
the US Census. The reliability and validity of the NHWS, 
particularly as it relates to disease prevalence, has been 
assessed in prior research.10–12 These studies have compared 
data  collected from the NHWS and various other sources, 
including the US Census Bureau’s Current  Population  Survey, 
National Health Interview Survey, National Health and 
Nutrition Examination Survey, and the Medical  Expenditure 
Panel Survey.10–12
Data from the 2012 NHWS were analyzed for this 
descriptive analysis. The NHWS was administered to a 
sample of adults who were identified through a web-based 
consumer panel. It is a cross-sectional, self-administered, 
web-based survey encompassing 100 various conditions. The 
diabetes condition series consists of 41 questions. Survey data 
for this analysis were collected during the first three quarters 
of 2012. The projected number of US adults diagnosed with 
diabetes from the NHWS aligned favorably with the estimate 
from the National Health Interview Survey results and is thus 
nationally representative.13
Participant selection
Participants were recruited through opt-in emails, 
 coregistration with other panels, e-newsletter campaigns, 
and online banner placements. The total sample size of the 
NHWS consisted of 71,157 participants. Participants were 
included in this analysis if they were adults aged 18 years 
or older who reported a diagnosis of T2DM. At the time of 
the survey, participants self-identified as taking prescription 
 antihyperglycemic agent(s) to treat diabetes.
Participant characterization
Hypoglycemia was identified by self-report by participants in 
response to questions in the survey. Participants were asked if 
they had ever experienced hypoglycemia or low blood sugar 
as a result of their diabetes, with examples of symptoms of 
hypoglycemia provided (shakiness, nervousness, sweating, 
dizziness-lightheadedness, sleepiness, confusion, difficulty 
speaking, anxiety, weakness, fainting, crying out or having 
nightmares, finding clothes or sheets damp from perspira-
tion, feeling tired, irritable, or confused after waking up). 
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 Participants were grouped into one of three potential hypogly-
cemia categories: those who had experienced  hypoglycemia 
within the previous 3 months (recent hypoglycemia); those 
who had experienced hypoglycemia in the past, but not 
in the previous 3 months (nonrecent hypoglycemia); and 
those who had never experienced hypoglycemia (never 
hypoglycemia).
Race/ethnicity, degree of blood glucose control, body 
mass index (BMI), Charlson Comorbidity Index (CCI) 
scores, medication adherence, health-related HRQoL, and 
work productivity were determined for each hypoglycemia 
category. For race/ethnicity, five categories were reported, 
ie, White, African American, Hispanic, Asian, and  American 
Indian. Participants with more than one race/ethnicity or 
who did not belong to one of the five main categories were 
excluded from this analysis. For the degree of blood glu-
cose control, participants self-reported their most recent 
HbA
1c
 level by responding to the question, “What is your 
hemoglobin A
1c
 level?” They were then categorized into 
one of five categories: low (,7.0%), slightly elevated 
($7.0% to #8.5%), elevated (.8.5% to #11.0%), seriously 
elevated (.11.0%), and those who did not know their HbA
1c
 
levels. BMI was calculated based on self-reported height 
and weight, then categorized into one of four categories: 
obese ($30 kg/m2), overweight (25 to ,30 kg/m2), normal 
weight ($19 to ,25 kg/m2), and underweight (,19 kg/m2). 
Mortality risk based on self-reported comorbid conditions 
was calculated using the CCI as another indicator of disease 
burden. Increasing CCI score has been shown to correlate 
with increased risk of mortality in people with T2DM.14,15 In 
order to remain true to the method of identifying all condi-
tions and diseases, diabetes remained a condition measured 
in the CCI and counted for one point.
Adherence characterization
Adherence to antidiabetic medications was determined 
using the Morisky Medication Adherence Scale (MMAS). 
The MMAS is a structured, self-reported measure with 
higher scores representing higher medication adherence. 
The English version of the eight-item MMAS (MMAS-8) 
has not been validated in patients with T2DM, but has been 
validated in hypertensive patients taking antihypertensive 
medications.16 The Malaysian version of the MMAS-8 and 
the four-item MMAS (MMAS-4) have been validated in 
patients with T2DM.17 The MMAS-8 has been assessed for 
its reliability and congruence with the MMAS-4 in T2DM 
patients taking antidiabetic medications which has shown 
that increased scores in the MMAS-4 are significantly 
 associated with decreasing HbA
1c
 levels.17–20 In this analysis, 
the eight-item questionnaire was truncated to seven items, 
eliminating the question “Do you sometimes forget to take 
your pills?” The question was removed to prevent confusion 
for those participants on insulin and other injectable medica-
tions in order to preserve their inclusion in the study. From 
a reliability assessment, the developer of the scale assessed 
the internal consistency of the seven-item scale and it did 
not significantly differ for reliability; removing the ques-
tion decreases the internal consistency (Cronbach’s α) of 
the MMAS-8 from 0.83 to 0.78.16 A MMAS score of 7 is 
categorized as high adherence, 5–6 is medium adherence, 
and ,5 is low adherence.
health-related quality of life
Quality of life was determined using the Short Form-36 
health survey (SF-36), version 2,21 and specific questions 
from the NHWS (eg, interference with normal social activi-
ties due to physical health or emotional problems, whether 
patients feel hassled about taking their antihyperglycemic 
medications, whether the participant had symptoms that 
required assistance from a health care practitioner). Physical 
and mental summary scores were derived based on scores 
from the eight domains of the SF-36 (physical functioning, 
role-physical, bodily pain, general health perceptions, vitality, 
social functioning, role-emotional, and mental health).
Work productivity
Work productivity was determined by absenteeism and 
presenteeism based on self-reported days/hours missed from 
work. Absenteeism is defined as the percentage of work 
time missed due to hypoglycemia-related health issues. 
 Presenteeism is defined as the percentage of overall work 
impaired by hypoglycemia-related health issues. Overall 
work productivity impairment is defined as the percentage of 
time missed due to either absenteeism or presenteeism.
statistical analysis
Statistical analyses were conducted with IBM SPSS Data 
Collection Quantum Version 5.8.1 (IBM Corp, Armonk, NY, 
USA). Group comparisons were performed using unpaired 
t-tests or analysis of variance for continuous variables and 
chi-square analysis for categorical variables.
Results
A total of 7,239 participants reported a diagnosis of T2DM 
(Table 1). Of those, 6,065 were treated with antihypergly-
cemic agents (oral and injectable agents). The mean age 
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was 60.6 years and the majority (60.3%) was male. A large 
proportion of participants (36.0%) did not know their HbA
1c
 
levels. In those who reported HbA
1c
, mean levels were 6.9%. 
Over 60% of participants had hypertension and/or high 
cholesterol.
Of the participants who were treated with antihypergly-
cemic agents (n=6,065), 5,756 (94.9%) knew their hypogly-
cemia status (Figure 1). Approximately 56% of participants 
who knew their hypoglycemia status had experienced 
hypoglycemia in the past (n=3,204). Approximately 29% 
(n=1,688) of those who knew their hypoglycemia status 
reported experiencing recent hypoglycemia. Over half (53%) 
of the participants with recent hypoglycemia required assis-
tance from another person (data not shown). Of the partici-
pants who had recent hypoglycemia and self-managed their 
episodes, 57% had hypoglycemia episodes monthly (data not 
shown). In participants who had recent hypoglycemia and 
needed assistance from another person, 43% had episodes 
2–6 times a year (data not shown).
Table 2 describes the demographic profile according 
to hypoglycemia group. Participant mean age ranged from 
59.2 years to 61.3 years. The recent hypoglycemia group had 
a lower proportion of male participants (55.8%) compared 
with the nonrecent hypoglycemia (59.4%, P,0.05) and never 
hypoglycemia (63.8%, P,0.05) groups. The race/ethnicity 
distributions were similar among the hypoglycemia groups.
Table 3 describes the incidence of hypoglycemia accord-
ing to diabetes-related clinical characteristics. The mean 
Table 1 characteristics of survey participants with T2DM who 
were treated with antihyperglycemic agents
n (%)
Participants reporting a diagnosis of T2DM 7,239
Treated participants with T2DM 6,065 (100.0)
Demographics
Mean age (years ± sD) 60.6±11.5
sex
 Male 3,655 (60.3)
 Female 2,410 (39.7)
race/ethnicity
 White 4,658 (76.8)
 African American 693 (11.4)
 hispanic 400 (6.6)
 Asian 128 (2.1)
 American indian 92 (1.5)
Clinical characteristics
hbA1c (%)
 low (,7.0%) 2,163 (35.7)
 slightly elevated ($7.0% and #8.5%) 1,299 (21.4)
 elevated (.8.5% to #11.0%) 247 (4.1)
 seriously elevated (.11.0%) 55 (0.9)
 Don’t know 2,186 (36.0)
 Mean ± sD 6.9±1.3
Mean BMi (kg/m2 ± sD) 33.8±7.7
ever experienced high cholesterol 3,784 (62.4)
ever experienced hypertension 3,867 (63.8)
Antihyperglycemic agents
 insulin 1,742 (28.7)
 Metformin 3,176 (57.3)
 sulfonylureas 2,101 (37.9)
 DPP-4 inhibitors 572 (10.3)
 glP-1 agonists 323 (5.8)
 Thiazolidinediones 530 (9.6)
Abbreviations: hbA1c, glycated hemoglobin; BMi, body mass index; DPP-4, dipeptidyl 
peptidase-4; glP-1, glucagon-like peptide-1; sD, standard deviation; T2DM, type 2 
diabetes mellitus.
T2DM total sample
N=7,239
No
N=1,174
No
N=309
No
N=2,552
No
N=1,516
Yes
N=6,065
Yes
N=5,756
Yes
N=3,204
Yes
N=1,688
Know HG history?
Ever had HG?
Recent HG (past 3 months)?
Treated with oral AHA, insulin, and/or injectable?
Figure 1 Description of population.
Abbreviations: hg, hypoglycemia; T2DM, type 2 diabetes mellitus; AhA, antihyperglycemic agent.
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HbA
1c
 levels were 7.1% in the recent hypoglycemia group, 
7.0% in the nonrecent hypoglycemia group, and 6.8% in the 
never hypoglycemia group. A larger percentage of partici-
pants in the never hypoglycemia group (40.9%) did not know 
their HbA
1c
 status compared with the recent hypoglycemia 
and nonrecent hypoglycemia groups (27.0% and 34.3%, 
respectively, P,0.05). A higher percentage of participants in 
the recent hypoglycemia group (29.5%) had slightly elevated 
HbA
1c
 levels ($7.0% to #8.5%) compared with the nonre-
cent hypoglycemia group (23.2%, P,0.05), both of which 
were significantly higher than the never hypoglycemia group 
(16.5%, P,0.05 for both). Due to the variability between 
groups in the percentage of participants who did not know 
or did not report their HbA
1c
 values, glycemic control was 
also examined only in the participants who reported their 
HbA
1c
 values (Table 4). In the total population, there were 
no significant between-group differences in the percentage of 
participants with low HbA
1c
 (,7.0%). However, in those who 
reported their HbA
1c
 values, a significantly lower  percentage 
Table 2 Hypoglycemic episodes by demographic profile in 
participants treated with antihyperglycemic agents
Recent HG 
(n=1,688)
Nonrecent HG 
(n=1,516)
Never HG 
(n=2,552)
Age, years
 18–44 212 (12.5%)a 132 (8.7%) 234 (9.2%)
 45–54 324 (19.2%)c 271 (17.9%) 416 (16.3%)
 55–64 490 (29.0%) 444 (29.3%) 694 (27.2%)
 65+ 662 (39.2%)a 669 (44.1%)c 1,208 (47.3%)
 Mean (years ± sD) 59.2±11.9a 60.9±10.9 61.3±11.5
sex
 Male 941 (55.8%)a 901 (59.4%) 1,629 (63.8%)
 Female 747 (44.3%)a 615 (40.6%)c 923 (36.2%)
race/ethnicity
 White 1,296 (76.8%) 1,154 (76.1%) 1,965 (77.0%)
 African American 168 (10.0%)b 196 (12.9%) 301 (11.8%)
 hispanic 118 (7.0%) 104 (6.9%) 159 (6.2%)
 Asian 31 (1.8%) 22 (1.5%)c 67 (2.6%)
 native American 42 (2.5%)a 17 (1.1%) 28 (1.1%)
Notes: aP,0.05 versus both nonrecent hg and never hg groups; bP,0.05 versus 
nonrecent hg group only; cP,0.05 versus never hg group only.
Abbreviations: hg, hypoglycemia; sD, standard deviation; T2DM, type 2 diabetes 
mellitus.
Table 3 Diabetes-related clinical characteristics by hypoglycemia category in participants treated with antihyperglycemic agents
n (%) Recent HG 
(n=1,688)
Nonrecent HG 
(n=1,516)
Never HG 
(n=2,552)
hbA1c
 low (,7.0%) 607 (36.0%) 533 (35.2%) 933 (36.6%)
  slightly elevated ($7.0% to #8.5%) 498 (29.5%)a 351 (23.2%)c 420 (16.5%)
  elevated (.8.5% to #11.0%) 96 (5.7%)c 65 (4.3%)c 78 (3.1%)
  seriously elevated (.11.0%) 14 (0.8%) 17 (1.1%) 21 (0.8%)
 Do not know 456 (27.0%)a 520 (34.3%)c 1,043 (40.9%)
 Mean (% ± sD) 7.1±1.3c 7.0±1.3c 6.8±1.3
Antihyperglycemic agentsd
 insulin 777 (46.0%)a 491 (32.4%)c 433 (17.0%)
 Metformin 790 (54.8%)c 772 (56.7%) 1,436 (58.8%)
 sulfonylureas 674 (46.7%)a 582 (42.7%)c 748 (30.6%)
 DPP-4 inhibitors 135 (9.4%)b 163 (12.0%) 248 (10.2%)
 glP-1 agonists 126 (8.7%)a 87 (6.4%)c 98 (4.0%)
 Thiazolidinediones 147 (10.2%) 156 (11.5%)c 206 (8.4%)
BMi (kg/m2)
 Obese ($30) 1,111 (67.3%)c 984 (66.7%)c 1,545 (61.9%)
 Overweight ($25 to ,30) 410 (24.8%)c 375 (25.4%)c 725 (29.0%)
 normal ($19 to ,25) 125 (7.6%) 111 (7.5%) 223 (8.9%)
 Underweight (,19) 5 (0.3%) 5 (0.3%) 4 (0.2%)
 Mean ± sD 34.0±7.7c 34.0±7.7c 33.3±7.6
cci score
 1 1,004 (59.5)c 947 (62.5)c 1,820 (71.3)
 2 317 (18.8)c 287 (18.9)c 392 (15.4)
 3 184 (10.9)c 166 (11.0)c 219 (8.6)
 4+ 183 (10.8)a 116 (7.7)c 121 (4.7)
 Mean ± sD 1.88±1.49a 1.72±1.22c 1.52±1.05
Notes: aP,0.05 versus both nonrecent hg and never hg groups; bP,0.05 versus nonrecent hg group only; cP,0.05 versus never hg group only; dantihyperglycemic 
agents are not mutually exclusive regimens.
Abbreviations: hbA1c, glycated hemoglobin; BMi, body mass index; cci, charlson comorbidity index; DPP-4, dipeptidyl peptidase-4; glP-1, glucagon-like peptide-1; 
hg, hypoglycemia; sD, standard deviation; T2DM, type 2 diabetes mellitus.
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The never hypoglycemia group had the lowest use of insulin 
(17.0%) compared with the nonrecent hypoglycemia (32.4%) 
and recent hypoglycemia (46%) groups (P,0.05 in both). The 
never hypoglycemia group also had the lowest use of sulfonyl-
urea and glucagon-like peptide-1 agonists (Table 3).
The mean BMI was 33.3 kg/m2 in the never hypoglycemia 
group and 34.0 kg/m2 in both the recent and nonrecent hypo-
glycemia groups (Table 3). More than 60% of participants 
were overweight or obese. Diabetes disease burden was 
higher in participants with hypoglycemia. The mean CCI 
score was highest in those with recent hypoglycemia (1.88) 
compared with those with nonrecent hypoglycemia (1.72; 
P=0.05 versus recent hypoglycemia) and never hypoglyce-
mia (1.52; P,0.05 versus both the recent hypoglycemia and 
nonrecent hypoglycemia groups).
Of all participants taking antihyperglycemic agents, 52% 
reported medium to low adherence with their medications, 
a quarter of whom had low adherence. The recent hypogly-
cemia group had the highest proportion of medium or low 
adherence followed by the nonrecent hypoglycemia and 
never hypoglycemia groups (Table 6).
Hypoglycemia had significant impact on participants’ 
lives. A larger proportion of participants in the recent hypo-
glycemia and nonrecent hypoglycemia groups reported 
moderately to extreme interference with social activities 
compared with the never hypoglycemia group (Table 7). 
Work productivity was also impacted. Those with recent 
hypoglycemia had significantly higher absenteeism (7.6%), 
presenteeism (21.3%), and total work productivity impair-
ment (25.5%) due to health compared with those with nonre-
cent hypoglycemia (4.4%, 15.1%, and 18.0%, respectively; 
P,0.05 for all comparisons) or never hypoglycemia (3.5%, 
14.0%, and 16.3%, respectively; P,0.05 for all comparisons; 
Figure 2). Overall, recent hypoglycemia episodes contributed 
to lower HRQoL. General health summary scores across all 
domains of the SF-36, physical and mental, were significantly 
lower in participants with recent hypoglycemia compared 
with those with nonrecent hypoglycemia or never hypogly-
cemia (P,0.05 for all comparisons; Figure 3).
Table 5 Percentage of participants reporting hypoglycemia by hbA1c level
n (%) Low  
(,7.0%) 
n=2,073
Slightly elevated  
($7% to #8.5%) 
n=1,269
Elevated 
(.8.5% to #11.0%) 
n=239
Seriously elevated 
(.11.0%) 
n=52
Do not know 
n=2,019
recent hg 607 (29.3)a 498 (39.2) 96 (40.2) 14 (26.9) 456 (22.6)b
nonrecent hg 533 (25.7) 351 (27.7) 65 (27.2) 17 (32.7) 520 (25.8)
never hg 933 (45.0)a 420 (33.1) 78 (32.6) 21 (40.4) 1,043 (51.7)b
Notes: aP,0.05 versus the slightly elevated, elevated, and do not know groups; bP,0.05 versus the low, slightly elevated, and elevated groups.
Abbreviations: hbA1c, glycated hemoglobin; hg, hypoglycemia.
Table 4 hbA1c levels by hypoglycemia category in participants 
who reported hbA1c levels
n (%) Recent HG 
(n=1,215)
Nonrecent HG 
(n=966)
Never HG 
(n=1,452)
low (,7.0%) 607 (50.0%)a 533 (55.2%)b 933 (64.3%)
slightly elevated  
($7.0% to #8.5%)
498 (41.0%)a 351 (36.3%)b 420 (28.9%)
elevated  
(.8.5% to #11.0%)
96 (7.9%)b 65 (6.7%) 78 (5.4%)
seriously elevated  
(.11.0%)
14 (1.2%) 17 (1.8%) 21 (1.5%)
Mean (% ± sD) 7.05±1.27b 6.98±1.27b 6.78±1.26
Notes: aP,0.05 versus both nonrecent hg and never hg groups; bP,0.05 versus 
never hg group only.
Abbreviations: hbA1c, glycated hemoglobin; hg, hypoglycemia; sD, standard 
deviation.
of those in the recent hypoglycemia group had low HbA
1c
 
(50.0%) compared with the nonrecent hypoglycemia group 
(55.2%, P,0.05), both of which were significantly lower than 
the never hypoglycemia (64.3%) group (P,0.05 for both). 
The relationship between hypoglycemia and the percentage 
of participants with slightly elevated HbA
1c
 was similar to 
that of the total population.
Conversely, the percentage of participants experienc-
ing hypoglycemia was examined based on HbA
1c
 group 
(Table 5). A significantly lower proportion of participants in 
the low HbA
1c
 group reported recent hypoglycemia (29.3%) 
compared with both the slightly elevated HbA
1c
 (39.2%) and 
elevated HbA
1c
 (40.2%) groups (P,0.05 for both). This cor-
responded to a significantly higher proportion of participants 
reporting never hypoglycemia (45.0%) compared with the 
slightly elevated HbA
1c
 (33.1%) and elevated HbA
1c
 (32.6%) 
groups (P,0.05 for both). In participants who reported not 
knowing their HbA
1c
 levels (n=2,019), the percentage that 
reported experiencing a recent hypoglycemia (22.6%) was 
significantly lower than for the low, slightly elevated, and 
elevated HbA
1c
 groups (P,0.05 for all). The percentage of 
participants who did not know their HbA
1c
 levels and reported 
never experiencing hypoglycemia (51.7%) was significantly 
higher than in the low, slightly elevated, and elevated HbA
1c
 
groups (P,0.05 for all).
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Discussion
Studies have shown that glycemic control deteriorates pro-
gressively over time, necessitating increased use of insulin 
therapy. Although this approach may lessen the deterioration, 
it may come at the expense of significant weight gain and 
hypoglycemia.22 Despite newer antihyperglycemic agent 
treatment options, such as the dipeptidylpeptidase-4 inhibi-
tors and glucagon-like peptide-1 agonists, a large proportion 
of people with T2DM still report experiencing  hypoglycemia. 
To our knowledge, this is the first large-scale study to char-
acterize the impact of hypoglycemia on diabetes burden, 
HRQoL, and work productivity from the patient perspective 
in a single analysis. The results of this study offer insight 
into the demographics and clinical characteristics of survey 
participants who experienced hypoglycemia (recent or non-
recent) or never experienced hypoglycemia. In addition, the 
results show that hypoglycemia negatively impacts social 
function, overall HRQoL, work productivity, and medica-
tion adherence.
The results suggest that adults with T2DM who experience 
hypoglycemia tend to be younger, be more aware of their 
HbA
1c
 levels and have higher HbA
1c
 levels, have higher BMIs, 
have higher CCI scores, be treated with insulin, sulfonylureas, 
or glucagon-like peptide-1 agonists, and be less adherent to 
their antihyperglycemic agents compared with those who 
never experience hypoglycemia. The impact appears even 
greater in those experiencing recent  hypoglycemia. Although 
we did not expect the never hypoglycemia group to have an 
older mean age than the nonrecent hypoglycemia or recent 
hypoglycemia groups, and we really do not know the reason 
behind these findings, we can speculate that older patients 
may be more prone to recall bias and other limitations inherent 
with surveys. Also, we may expect the risks of hypoglycemia 
to increase with advancing age, but the recognition of hypo-
glycemia signs may decrease.
The association of hypoglycemia with poor glycemic con-
trol is consistent with the notion that the fear of hypoglycemia 
leads to maintenance of higher glycemic levels, although 
there is little evidence in the literature to support this.5,8 The 
results of this study would add support, as almost twice the 
percentage of those with recent hypoglycemia (29.5%) had 
slightly elevated HbA
1c
 levels (7.0%–8.5%) compared with 
those who never had hypoglycemia (16.5%). The association 
between hypoglycemia and poor medication adherence is 
consistent with other observations in the literature. A data-
base analysis using the 2006–2008 NHWS found a signifi-
cant association between the number of tolerability issues 
(hypoglycemia, constipation/diarrhea, headaches, weight 
gain, and water retention) and medication nonadherence in 
participants with T2DM. Each additional tolerability issue 
was associated with a 28% greater likelihood of medication 
nonadherence.23 A European study in people with T2DM that 
added a sulfonylurea or a thiazolidinedione to ongoing met-
formin therapy reported that those with hypoglycemia were 
significantly more likely to report barriers to adherence.24 
A study drawing on a large administrative database of man-
aged care plans (Impact database; Ingenix) showed that in 
people with T2DM on one or more oral antihyperglycemic 
agents, having one or more hypoglycemic events within a 
6-month interval was significantly associated with treatment 
discontinuation over this period and the subsequent 6-month 
interval.25 There has been an association observed between 
better medication adherence and better glycemic control in 
people with T2DM.20,26 The results of this study show that 
hypoglycemia may be a significant factor in medication 
adherence and glycemic control, given that both were poorer 
in those having nonrecent hypoglycemia compared with 
those never having hypoglycemia, and were even worse in 
those with recent hypoglycemia compared with those with 
nonrecent hypoglycemia.
Poor medication adherence and glycemic control in 
people with T2DM with hypoglycemia may be a result of 
the additional burden caused by fear of hypoglycemia and the 
need to manage it. Diabetes is a chronic disease that involves 
Table 6 Morisky Medication Adherence scale scores in participants 
taking antihyperglycemic agents
Adherence  
score
Recent HG 
(n=1,688)
Nonrecent HG 
(n=1,516)
Never HG 
(n=2,552)
high (7) 660 (39.1%)a 691 (45.6%)b 1,411 (55.3%)
Medium (5–6) 733 (43.4%)b 607 (40.0%)b 901 (35.3%)
low (,5) 295 (17.5%)a 218 (14.4%)b 240 (9.4%)
Notes: aP,0.05 versus both nonrecent hg and never hg groups; bP,0.05 versus 
never hg group only.
Abbreviation: hg, hypoglycemia.
Table 7 extent of interference with social activities in the 
previous 4 weeks in participants taking antihyperglycemic agents 
by hg experience
Frequency Recent HG 
(n=1,688)
Nonrecent HG 
(n=1,516)
Never HG 
(n=2,552)
not at all 615 (36.4%)a 691 (45.6%) 1,437 (56.3%)
slightly 433 (25.7%)b 349 (23.0%) 537 (21.0%)
Moderately 319 (18.9%)b 255 (16.8%)b 342 (13.4%)
Quite a bit 235 (13.9%)a 166 (11.0%)b 176 (6.9%)
extremely 86 (5.1%)a 55 (3.6%)b 60 (2.4%)
Notes: aP,0.05 versus both nonrecent hg and never hg groups; bP,0.05 versus 
never hg group only.
Abbreviation: hg, hypoglycemia.
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constant monitoring of behaviors and habits (eg, eating, social 
activities, exercise) in order to maintain proper glycemic 
control, and hypoglycemia appears to add to these burdens. 
Study participants who had a previous hypoglycemia reported 
feeling more “hassled” about taking their antihyperglyce-
mic agents compared with participants who had never had 
 hypoglycemia (data not reported). Increased interference with 
social activities, missed work, and work impairment were also 
reported in those with hypoglycemia and more so in those 
with recent hypoglycemia. Thus, it is no surprise that overall 
HRQoL decreased in those with nonrecent hypoglycemia and 
decreased further in those with recent hypoglycemia.
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Figure 2 Work productivity in participants taking antihyperglycemic agents.
Notes: Absenteeism refers to mean percentage of work time missed due to health (currently employed full-time people); presenteeism refers to mean percentage 
impairment while working due to health (currently employed full-time people); work productivity impairment refers to mean overall work impairment due to health. aP,0.05 
versus nonrecent hg. bP,0.001 versus never hg. cP=0.001 versus nonrecent hg.
Abbreviation: hg, hypoglycemia.
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Figure 3 general health summary scores (short Form-36) in participants taking antihyperglycemic agents who know their hypoglycemic status.
Abbreviations: PF, physical functioning; rP, role-physical; BP, body pain; gh, general health; VT, vitality; sF, social functioning; re, role-emotional; Mh, mental health; hg, 
hypoglycemia.
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Hypoglycemia is associated with significant morbidity 
and mortality, which further adds to the burden for people 
with T2DM.27 In this study, mean CCI scores were highest in 
participants with recent hypoglycemia, followed by those who 
had nonrecent hypoglycemia and those who never had hypo-
glycemia. The higher disease burden and risk of mortality in 
those with hypoglycemia is consistent with observations that 
hypoglycemia may increase morbidity and mortality in people 
with T2DM. In a post-hoc analysis of the ADVANCE (Action 
in Diabetes and Vascular  Disease:  Preterax and  Diamicron 
Modified-Release Control Evaluation) trial, severe hypo-
glycemia was associated with significant increases in the 
risks of major microvascular and macrovascular events and 
deaths.28 In the ACCORD (Action to Control Cardiovascu-
lar Risk in Diabetes) and ADVANCE trials, patients with a 
history of severe hypoglycemia events had approximately 
a 1.4-fold to 3-fold higher risk of mortality, with one-third 
to one-half of all deaths being cardiovascular in nature. 
However, it is not known if severe hypoglycemia contributes 
to adverse outcomes or if it is a marker of vulnerability to 
these events.28,29
Because this analysis is based on a patient survey, there 
are caveats to keep in mind when interpreting its find-
ings. The data collected are subject to recall bias, missing 
values, and variability in the interpretation of questions. 
Certain characteristics such as BMI and CCI were based 
on patient self-reported information and, thus, may be 
susceptible to bias. In addition, due to limitations regard-
ing how the data were collected and the descriptive nature 
of the study, there were no adjustments for factors such as 
severity of hypoglycemia and unknown HbA
1c
 levels. The 
descriptive nature of the study also precludes any definitive 
conclusions regarding causality being made in any of the 
observed relationships. Furthermore, the survey depended 
on participant interpretation and reporting of hypoglycemia 
episodes as opposed to biochemical documentation with a 
glucose reading. Finally, the survey was Internet-based, and 
so may not be fully representative of the entire population 
with T2DM given that it only includes participants who have 
computer access and a degree of computer literacy. Thus, 
although certain demographic characteristics (eg, sex, age, 
region) approximate the US census population, this survey 
sample may not be completely generalizable to the entire 
population with T2DM.
Conclusion
The results of this study highlight the significant burden of 
hypoglycemia from a patient perspective and its impact on 
HRQoL, work productivity, and medication adherence. The 
causes of hypoglycemia are likely multifactorial. Patient 
education regarding hypoglycemia early in the disease course 
may be helpful, since the fear of future hypoglycemia events 
may result in poor medication adherence and glycemic con-
trol that could lead to the development of long-term T2DM-
associated complications. Another important consideration 
is the selection of antihyperglycemic treatment, given that 
certain classes of medications are associated with higher 
risks of hypoglycemia. This analysis focused on patients’ 
perspectives of hypoglycemia, but it is also important to 
consider the impact of hypoglycemia in other areas. From 
the perspectives of the health care provider, payer, and 
employer, increasing attention towards hypoglycemia in 
people with T2DM may increase work productivity and 
decrease health care utilization. These results support the 
need for multi-modal approaches, including careful selection 
of medication regimens, to minimize the risk and burden of 
hypoglycemia.
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